Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Supreme Court Signals Doubts Over Trump’s Bid to Fire Fed Governor Lisa Cook 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Norway Opens Corruption Probe Into Former PM and Nobel Committee Chair Thorbjoern Jagland Over Epstein Links 
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
Federal Judge Restores Funding for Gateway Rail Tunnel Project 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
Bristol Myers Squibb has sued AstraZeneca for its antibody-based cancer treatment Imjudo, which it says infringes its patents for its drug Yervoy
According to Bristol Myer, Imjudo fights cancer in the same way as Yervoy.
Bristol Myers has previously sued AstraZeneca for patent infringement over the latter’s other cancer drug, Imfinzi.
AstraZeneca said it is aware of the complaint and will respond to it "at the appropriate time."
The FDA has also approved the immunotherapy Yervoy for the treatment of kidney, lung, colorectal, and other cancers. The FDA initially approved Yervoy in 2011 to treat melanoma.
In 2021, Bristol Myers sold over $2 billion worth of Yervoy.
AstraZeneca’s Imjudo was given FDA approval last year to be used in conjunction with Imfinzi to treat liver and lung cancer.
In the second lawsuit, Bristol Myers claimed that AstraZeneca had violated two patents on the use of antibodies to treat cancer and strengthen a patient's immune system.
Bristol Myers insists that AstraZeneca was aware of the patents, being on notice due to licensing discussions and the Imfinzi lawsuit.
The lawsuit seeks an unspecified amount of money for damages.
